Israel Steps Closer to Cannabis Legalization

Israel Steps Closer to Cannabis Legalization

Original Post: CFN Media Group: Israel Steps Closer to Cannabis Legalization

[Canniseur: I know the trumpet is getting loud about legalizing cannabis around the world. The racism of prohibition is beginning to be seen for what it is and was; A systemic and racist stab at control of people. And since Israel is the land of the Bible and cannabis is all over the Bible, all I can say is; “Go for it Israel!”]

Israel could become the next country to legalize adult-use cannabis after lawmakers gave preliminary approval to two bills calling for the decriminalization of cannabis and the regulation of its sale for recreational and medical use.

Let’s take a closer look at the move and what it means for public companies operating in the country, including Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF)—the only Israeli pure-play opportunity in the space.

Legalization on the Horizon

The Israeli government’s approval of two preliminary cannabis bills would decriminalize the possession and use of small quantities of cannabis, as well as create a regulatory framework governing the sale of adult-use and medical cannabis in the country. While the discussions remain early-stage, it could mirror that of Canada or other legal countries.

Israel has a burgeoning medical cannabis industry already that has more than 50,000 authorized users and that figure is rapidly growing. At the same time, the country has some of the highest per capita cannabis usage rates in the world at nearly one-third of people between the ages of 18 and 65—creating an enormous market opportunity.

Click here to learn more about being an early investor in the Israeli cannabis market

In addition to its legalization efforts, Israel has long been a leader in cannabis research and development. The country became the first country in the world to allow medical research and cultivation back in 2007, while THC and CBD cannabinoid structures were originally discovered at Hebrew University of Jerusalem.

The Israeli Cabinet approved the export of medical cannabis back in 2019 and the government gave the final go-ahead earlier this year. The move could open the door to exports to the European Union, which is located nearby and represents a massive and underserved market for medical cannabis and CBD products.

Capitalizing on the Market

There are several public and private companies targeting the Israeli cannabis industry, but few of them are pure-plays that trade on North American exchanges.

Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF) has an expected annual capacity of more than 23,000 kilograms of dried cannabis at its Cannisra farm and with Israel’s favorable climate, management anticipates becoming a low-cost cannabis producer with costs of just $0.40 per gram—translating to attractive margins.

Click the image below to view a brief overview of the cannabis opportunity in Israel

Additionally, in the Hefer Valley region, the company’s joint venture farm, Cannation Ltd., is nearing the completion of phase one construction and already has signed an offtake agreement with Israeli licensed producer Focus Medical Herbs Ltd. The property contains a 55,000 sq. ft. greenhouse that’s complete and awaiting final security inspection and a 110,000 sq. ft. facility for use as expansion.

Click here to learn more about being an early investor in the Israeli cannabis market

“From our ongoing development efforts at our initial Cannisra Holdings project, to our exciting advancements in the Hefer Valley, we’ve mapped out an integrated package of properties with a multi-greenhouse strategy which includes a network of important partners and stakeholders across Israel and Europe,” said CEO Darryl Jones.

Looking Ahead

Israel is rapidly progressing toward domestic legalization and the export of medical cannabis to the undersupplied European Union. Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF) is well positioned to capitalize on these dynamics with its various ongoing projects and agreements that are close to reaching a commercialization point.

For more information, visit the company’s website at www.isracann.com.

Click here to learn more about being an early investor in the Israeli cannabis market

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

The post Israel Steps Closer to Cannabis Legalization appeared first on CannabisFN.

Original Post: CFN Media Group: Israel Steps Closer to Cannabis Legalization

Pasha Partners with Indiva to Bring High-Quality Artisanal Cannabis to Market

Pasha Partners with Indiva to Bring High-Quality Artisanal Cannabis to Market

Original Post: CFN Media Group: Pasha Partners with Indiva to Bring High-Quality Artisanal Cannabis to Market

[Canniseur: This is, more or less, a promotional piece. It’s being published because they are taking the concept of ‘quality’ in cannabis to a different business model. If the cannabis is better and has a better effect or a more directed effect, then it’s going to be worth it to see how players in the cannabis business promote lower yeild, artisnal growers, although they never spell out what artisnal means.]

New partnership highlights the expertise of Canadian micro-growers

Source: Pasha Brands Ltd.

VANCOUVER, British Columbia, May 13, 2020 (GLOBE NEWSWIRE) — Pasha Brands Ltd. (the “Company” or “Pasha”) (CSE: CRFT) (OTC:CRFTF) (FSE:ZZD1) is pleased to announce it has signed a master processing agreement (the “MPA”) with Indiva Limited (“Indiva”) (TSXV:NDVA) (OTCQX:NDVAF) to manufacture and distribute pre-rolls and jarred flower curated from Pasha’s wholly-owned subsidiary, BC Craft Supply Co Ltd.’s, vast national network of artisanal cannabis growers. This partnership intends to elevate the premium cannabis playing field by highlighting the skills of Canada’s micro-growers and making their unique and beautiful flower available to consumers from coast-to-coast.

“This partnership represents a significant step for Pasha in realizing its vision to bring high-quality micro producers into the legal market and to provide an avenue for those products to be available on store shelves,” said Matthew Watters, Pasha’s Chief Executive Officer. “Our partnership with Indiva will leverage their world-class manufacturing capabilities, and equally strong distribution network within Canada, to produce pre-rolls and jarred flower that sets new industry standards. We take a lot of pride in our network of micro producers and are excited to work collaboratively to bring their artisanal cannabis to market, particularly at a time when quality product is in high demand.”

The MPA is for a one-year renewable term. The partnership expects to begin processing cannabis by late May 2020. Pasha and Indiva will share in the net revenue from the MPA after costs are recovered by each respective party.

For further information, please contact Pasha’s Chief Executive Officer, Matthew Watters, at (604) 687-2038.

About Pasha Brands

Based in British Columbia, Pasha is both North America’s largest network and aggregator of craft cannabis and Canada’s only prohibition-era brand house firmly rooted in the culture and made up by the people that created the original cannabis industry. With proven capabilities in cannabis cultivation, genetic research and development, product processing, and retail, Pasha is uniquely positioned in the new legal cannabis market through its network of hundreds of craft cannabis suppliers under the Pasha umbrella.

Pasha subsidiary, Medcann Health Products Ltd., is a Health Canada licensed cultivator and processor with a licence to sell medical cannabis products in Canada.Pasha, and its subsidiary BC Craft Supply Co. Ltd, assists micro cultivation farmers in bringing craft quality into the newly legal cannabis market in Canada by assisting them in both gaining access to licensing but also through its proprietary quality assurance and testing platform known as Craft Labs™, a proprietary platform bringing quality assurance to the craft industry, BC Craft Supply is driven to assist craft growers in obtaining security clearance and licensing to grow as micro-cultivators, specializing in education and compliance to bring growers into the regulated cannabis supply market.

Pasha’s common shares trade on the CSE under the symbol “CRFT” and on the FSE under the symbol “ZZD1”.

For more information, please visit www.pashabrands.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.  Accordingly, readers should not place undue reliance on forward-looking statements.  Pasha disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Related Articles

More articles issued by Pasha Brands Ltd.
More articles related to:
Partnerships

The post Pasha Partners with Indiva to Bring High-Quality Artisanal Cannabis to Market appeared first on CannabisFN.

Original Post: CFN Media Group: Pasha Partners with Indiva to Bring High-Quality Artisanal Cannabis to Market

Wana Quick Fast-Acting Gummies launch with Happy Hour Inspired Flavors

Wana Quick Fast-Acting Gummies launch with Happy Hour Inspired Flavors

Original Post: CFN Media Group: Wana Quick Fast-Acting Gummies launch with Happy Hour Inspired Flavors

[Canniseur: Wana gummies have been the most consistent edibles I’ve found. The effect seems the same every time. The indica flavor is great for long plane rides and helping sleep with pain. I’ve not been a fan of the ‘sativa’ flavor, mostly because I personally don’t like the effect of edibles. These new products might be different. They use a process called nanoemulsification, which is a pharmaceutical industry method of getting a drug in the bloodstream rapidly. It’s been around for a decade so it’s an established process. I’ll try them to see if the effect is different from regular edibles.]

Nanoemulsification technology ensures rapid onset and quicker offset

Boulder, Colo. (March 9, 2020) — Wana Brands continues to innovate the landscape of the gummie edible market. Wana Quick Fast-Acting Gummies featuring new Happy Hour flavors provide a novel edible experience, with an onset of 5-15 mins and Delta-9-THC effects (similar to an inhalation effect rather than an edible effect) lasting up to three hours. Traditional edibles have an onset time of up to two hours, with effects lasting up to six hours. The new Wana product line features an all-natural recipe, with no high fructose corn syrup. Each gummie offers 5mg of THC, with 20 gummies per package.

“At Wana, we saw a need for a product that could deliver a less intense inhalation-like experience in an edible form quickly and predictably,” said Wana CEO Nancy Whiteman. “Wana Quick Fast-Acting Gummies more closely mirror the onset and offset time of a typical inhalable cannabis product or an alcoholic beverage, making them a unique alternative to the traditional edible experience.”

Fast, effective and innovative, Wana Quick Fast-Acting Gummies harness TiME (Thermodynamic Individual Molecular Encapsulation), a new quick onset technology from Azuca. While traditional edibles convert Delta-9-THC in the digestive tract to 11-Hydroxy-THC, Wana Quick gummies feature individually encapsulated Delta-9-THC cannabinoids with greater bioavailability that work at the molecular level to bypass the liver and enter the bloodstream immediately. This means onset in less than 15 mins for most, and a Delta-9-THC experience that lasts two to four hours.

The encapsulation technology is paired with new flavors from Wana including:

●      CBD/THC 1:1 Strawberry Margarita: Fast-acting technology is paired with sweet and citrusy flavors of a strawberry margarita with a hint of salt. Infused with CBD and THC terpene-enhanced distillate, this popular 1:1 ratio offers psychoactive effects while promoting relaxation and tranquility. 5mg CBD / 5mg THC per piece, 100mg CBD / 100mg THC per package (20 pieces).

●      Sativa Peach Bellini: Fast-acting technology is paired with the juicy peach flavor of a sparkling peach bellini. Infused with sativa terpene-enhanced distillate, which has been known to cause a more uplifting and motivating effect. 5mg THC per piece, 100mg THC per package (20 pieces).

●      Indica Piña Colada: Fast-acting technology is paired with the rich and creamy pineapple and coconut flavors of a piña colada. Infused with indica terpene-enhanced distillate, which often results in a mellow, stress-relieving effect. 5mg THC per piece, 100mg THC per package (20 pieces).

Wana Quick Fast-Acting Gummies are now available in Colorado dispensaries and will roll out to other states where Wana Brands is available in the coming year. Wana became the No. 1 brand of edibles (BDS Analytics Brand Share Report 2019) in the United States, with more dollars sold than any other brand, by leading the industry in innovation. It has expanded its product portfolio with a range of different CBD/THC ratios as well as a variety of different dosages, onset times and duration of effects. The portfolio is designed so that products can be used singly or in combination to address specific health, wellness and recreational needs.

Another reason for the popularity of Wana’s gummies: great flavor. From the beginning, Wana has focused as much on taste as on all the other qualities of its products. More than 30 different types of pectin were tested to determine the best possible consistency and scalability. Fruit pectin makes Wana Sour Gummies one of the only available vegan products on the market. During the cooking process, the gummies are infused with a high-quality tincture, not sprayed. All Wana products are made with gluten-free ingredients and taste like real fruit, thanks to all-natural flavoring, coloring and sugar. Wana gummies contain no mineral oil or artificial sweeteners, which can cause stomach upset. Wana has prioritized safety and product standards. Products are manufactured in line with cGMP and HACCP practices and are tested for potency.

Wana Brands: Enhance Your Life.

Included in the 2019 Inc. 5000 list at #1536 and boasting a three-year growth rate of 269%, Wana Brands is the No. 1 edibles brand in the United States, with more dollars sold than any other brand, according to BDS Analytics 2019 Brand Share Report. Wana leads the industry in quality, consistency and potency, providing a range of different options that enable customers to create the specific cannabis experience they want. Wana products offer diverse product forms including edibles, vapes and extended release capsules, four different CBD/THC ratios as well as a variety of different dosages, onset times and duration of effects. The portfolio is designed so products can be used singly or in combination to address specific health, wellness and recreational needs. Wana products are available in Colorado, California, Ohio, Illinois, Michigan, Arizona and Oregon dispensaries, with Maryland, Oklahoma, Missouri, and Florida (as regulations allow) among the states imminently coming online. Wana Brands will also expand internationally to Canada in 2020. For more information or to subscribe to Wana’s e-newsletter, visit www.wanabrands.com. Follow Wana on LinkedIn, Twitter, YouTube and Pinterest.

The post Wana Quick Fast-Acting Gummies launch with Happy Hour Inspired Flavors appeared first on CannabisFN.

Original Post: CFN Media Group: Wana Quick Fast-Acting Gummies launch with Happy Hour Inspired Flavors

Vireo Health Launches 1937 Cannabis Brand

Vireo Health Launches 1937 Cannabis Brand

Original Post: CFN Media Group: Vireo Health Launches 1937 Cannabis Brand

[Canniseur: Interesting name. 1937 was the year that cannabis was first banned in the U.S. The company advertises that they are featuring historic cannabis strains. Um, no they’re not. Bubba Kush and Sweet Cheese are not the landrace (original) strains that they are purported to be. The story goes on to state that they use a long curing process, etc. I’d sure like to see this cannabis. If companies continue this kind of undocumented hype, they’ll hurt many other companies trying to grow special products.]

1937 Cannabis features historic cannabis strains and will be available in both dry flower and concentrates

MINNEAPOLIS, Oct. 17, 2019 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO; OTCQX: VREOF), a leading physician-founded, science-focused multi-state cannabis company, today announced the launch of 1937 Cannabis, a new brand of professional grade cannabis-based products. 1937 Cannabis represents the Company’s first launch of a new cannabis brand and first time offering dry flower. The 1937 Cannabis product line features dry flower and will expand to include concentrates later this year.

1937 Cannabis (www.1937cannabis.com) is now available in dispensaries throughout Pennsylvania and Maryland and features legendary strains such as ‘Bubba Kush’ and ‘Sweet Cheese’ that are handpicked and hand-packaged to assure only the best flower is utilized. The flower is cured for extended time periods to create a smoother taste, enhanced terpene profile, and deeper aromatics. 1937 Cannabis is 100% pesticide free and sold in premium, airtight glass jars.

“We are excited to announce the launch of 1937, a new line of premium-quality cannabis products,” said CEO and Founder Kyle Kingsley, MD. “By expanding our product lines to include dry flower, we are increasing access and affordability, while providing our customers – both cannabis connoisseurs and medical patients alike – with new choices and opportunities to discover which products best meet their individual needs.”

“Vireo is developing a strong portfolio of brands that engage and delight both recreation and medical consumers,” added Harris Rabin Chief Marketing Officer of Vireo Health. “1937 is our second major brand, but we are creating and launching a variety of exciting, new brands for every occasion our customers have to enjoy cannabis products.”

The brand name, 1937, is a reference to The Marihuana Tax Act of 1937, federal legislation designed to prohibit cannabis use. As Americans across the country work to end cannabis prohibition, the 1937 brand proudly stands for social justice and equality for all.

The Company plans to expand the 1937 Cannabis product line in Pennsylvania and Maryland and to make it available in other state-based markets in which Vireo is licensed to operate.

Learn more at: www.1937cannabis.com/ or follow the brand on Instagram www.instagram.com/1937cannabis/.

About Vireo Health International, Inc.
Vireo Health International, Inc.’s mission is to build the cannabis company of the future by bringing the best of medicine, engineering and science to the cannabis industry. Vireo’s physician-led team of nearly 400 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The Company currently is licensed in eleven markets including Arizona, Maryland, Massachusetts, Minnesota, New Mexico, New York, Nevada, Ohio, Pennsylvania, Puerto Rico, and Rhode Island. For more information about the Company, please visit www.vireohealth.com.

Contact Information

Media Inquiries
Albe Zakes
Vice President, Corporate Communications
albezakes@vireohealth.com
(267) 221-4800

Investor Inquiries
Sam Gibbons
Vice President, Investor Relations
samgibbons@vireohealth.com
(612) 314-8995

 

 

The post Vireo Health Launches 1937 Cannabis Brand appeared first on CannabisFN.

Original Post: CFN Media Group: Vireo Health Launches 1937 Cannabis Brand

Israel Builds Dominant Position in the Global Medical Cannabis Industry

Israel Builds Dominant Position in the Global Medical Cannabis Industry

Original Post: CFN Media Group: Israel Builds Dominant Position in the Global Medical Cannabis Industry

[Canniseur: Why should anyone be surprised by this? Israel has been dominant in cannabis research for decades. Now Israel is building itself to be one of the leaders, if not the leader in cannabis research and supply for the medical industry. Although this is a sponsored article, it’s worthwhile to note what Israeli science is doing to promote what is emerging as the single most potent plant (other than food crops) that can benefit humans.]

Israel has always been a leader in cannabis research and development—thanks to Raphael Mechoulam’s groundbreaking research—but it’s just starting to realize the potential for cultivation. In addition to having one of the highest per capita usage rates in the world, Israel is expected to soon have upwards of 50,000 patients on a waitlist and is uniquely located to become a major supplier to Germany and other European end markets.

Isracann Biosciences Inc. [CSE: IPOT (Pending)] aims to become Israel’s first pure-play cannabis firm listed in Canada with a four-pronged focus on cultivation, distribution, products and manufacturing, and R&D genetics.

Click Here To Receive Isracann’s Investor Presentation

Why Israel Stands at the Forefront

Israel is a well-known global science and technology hub with more than four percent of its GDP devoted to civil research and development and 140 scientists and technicians per 10,000 employees. Most investors are familiar with Israeli companies like Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Wix.com Ltd. (NASDAQ: WIX) that were born from this devotion to cutting-edge research and development.

Not surprisingly, Israel has also become a leader within the nascent cannabis industry. Raphael Mechoulam is widely recognized as the “Godfather of Cannabis” for discovering tetrahydrocannabinol (THC) and other cannabinoids. Earlier this year, the country doubled down on medical cannabis research by pouring $2.13 million into 13 cannabis research projects, making it one of just three countries with government funding for research.

Earlier this year, the Israeli Ministry of Agriculture officially classified the growing of medical cannabis as a ‘farming sector’, which paves the way for cannabis cultivators to receive government aid, grants, and water quotas like any other farmer. The Ministry of Health and Finance also recommended legalizing the export of medical cannabis, which experts believe could open the door to a $1 billion per year export market.

Building a Massive Footprint

Isracann is building 230,900 sq. ft. of hybrid greenhouses for the ultra-low-cost production of high-quality medical cannabis. Management expects these facilities to be completed by year end with an initial production capacity of 11,500 kilograms per year with the long-term goal of reaching 23,500 kilograms per year. The hybrid greenhouse has several advantages over indoor purpose-built greenhouses, including precise environmental controls and containment.

Through a distribution partnership in Malta, the company plans to efficiently export cannabis products to the European Union—and Germany in particular. The German market has 82.7 million citizens and serves as a key gateway to other European end markets, which could exceed North American end markets over time. New legislation passed earlier this year could pave the way for a new legal import framework.

While the company plans to deliver high-quality GMP flower for export in the early stages, management plans to expand into higher margin products, such as ultra-pure cannabinoid distillate that can be infused into a variety of products. At the same time, the company has partnered with leading research institutions and imports genetics from Canada and Holland to ensure that it’s offering the most competitive premium products.

Looking Ahead

Isracann Biosciences Inc.[CSE: IPOT (Pending)] is uniquely positioned to become a leader in Israel’s nascent cannabis industry. With a massive cultivation footprint and a four-pronged business plan, the company could begin generating revenue as early as next year. The country’s long-term potential to be a leader in R&D and a well-positioned exporter to Europe could make it the next big global cannabis destination.

Click Here To Receive Isracann’s Investor Presentation

For additional information, visit the company’s website at www.isracann.com.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Original Post: CFN Media Group: Israel Builds Dominant Position in the Global Medical Cannabis Industry

Cannabis News Highlights
Get Free Weekly News

Subscribe and get the best cannabis news of the week delivered directly to you.

Thank you for subscribing.

Something went wrong.